Recent director dealings and insider transactions at Bristol-Myers Squibb Company (BMY),
from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
Date
Insider
Type
Shares
2026-06-30
Samuels Theodore R. Ii
BUY
889
2026-06-30
Mcmullen Michael R.
BUY
607
2026-06-30
Rice Derica W
BUY
673
2026-06-30
Arduini Peter J
BUY
607
2026-06-30
Yale Phyllis R
BUY
607
2026-06-15
Haller Julia A
SELL
20,460
2026-06-15
Haller Julia A
BUY
20,460
2026-06-03
Short Bartie Wendy
SELL
8,040
2026-06-03
Short Bartie Wendy
SELL
3,876
2026-06-03
Short Bartie Wendy
BUY
8,040
Valuation
P/E RatioN/A
Market CapN/A
Beta0.235
Dividend/yrNone
52W High$62.89
52W Low$42.52
52-Week Range
$42.52Now$62.89
87% through annual range
From 52W High−4.3%
From 52W Low+41.5%
📖 Plain English Summary
Bristol-Myers Squibb Company is at 87% of its 52-week range. Beta 0.235 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for BMY🟢 Bullish⬜ Neutral🔴 Bearish
🤖
DipBuster AI Analysis — BMY
Heuristic · balance sheet, insider filings, price data, academic research
Bristol-Myers Squibb Company — DipBuster Score 16/100
Graham value assessment, NCAV analysis, price zones...
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's…
